ABSTRACT
Cu(CF3 COO)2 reacts with tert-butylacetylene (tBuC≡CH) in methanol in the presence of metallic copper powder to give two air-stable clusters, [CuI15 (tBuC≡C)10 (CF3 COO)5 ]â tBuC≡CH (1) and [CuI16 (tBuC≡C)12 (CF3 COO)4 (CH3 OH)2 ] (2). The assembly process involves in situ comproportionation reaction between Cu2+ and Cu0 and the formation of two different clusters is controlled by reactants concentration. The clusters consist of Cu15 and Cu16 cores co-stabilized by strong by σ- and π-bonded tert-butylethynide and CF3 COO- (together with methanol molecule in 2). Their stabilities in solution were confirmed using electrospray ionization mass spectrometry in which the cluster core remains intact for 1 in chloroform and acetone, and for 2 in acetonitrile. Strong thermochromic luminescence in the near infrared (NIR) region was observed in the solid-state. Of particular interest, the emission maximum of 1 is red-shifted from 710â nm at 298â K to 793â nm at 93â K, along with a 17-fold fluorescence enhancement. In contrast, 2 exhibits red shift from 298 to 123â K followed by blue shift from 123 to 93â K. The emission wavelength was correlated with the structural parameters using variable-temperature X-ray single-crystal analyses. The rich cuprophilic interaction plays a significant role in the formation of 3 LMCT (tBuC≡CâCux ) excited state mixed with cluster-centered (3 CC) characters, which can be considerably influenced by temperature, leading to thermochromic luminescence. The present work provides 1)â a new synthetic protocol for the high-nuclear CuI -alkynyl clusters; 2)â a comprehensive insight into the mechanism of thermochromic luminescence; 3)â unusual emissive materials with the characters of NIR and thermochromic luminescence simultaneously.
ABSTRACT
<p><b>BACKGROUND</b>Glioblastoma is the most common and lethal cancer of the central nervous system. Global genomic hypomethylation and some CpG island hypermethylation are common hallmarks of these malignancies, but the effects of these methylation abnormalities on glioblastomas are still largely unclear. Methylation of the O6-methylguanine-DNA methyltransferase promoter is currently an only confirmed molecular predictor of better outcome in temozolomide treatment. To better understand the relationship between CpG island methylation status and patient outcome, this study launched DNA methylation profiles for thirty-three primary glioblastomas (pGBMs) and nine secondary glioblastomas (sGBMs) with the expectation to identify valuable prognostic and therapeutic targets.</p><p><b>METHODS</b>We evaluated the methylation status of testis derived transcript (TES) gene promoter by microarray analysis of glioblastomas and the prognostic value for TES methylation in the clinical outcome of pGBM patients. Significance analysis of microarrays was used for genes significantly differently methylated between 33 pGBM and nine sGBM. Survival curves were calculated according to the Kaplan-Meier method, and differences between curves were assessed using the log-rank test. Then, we treated glioblastoma cell lines (U87 and U251) with 5-aza-2-deoxycytidines (5-aza-dC) and detected cell biological behaviors.</p><p><b>RESULTS</b>Microarray data analysis identified TES promoter was hypermethylated in pGBMs compared with sGBMs (P < 0.05). Survival curves from the Kaplan-Meier method analysis revealed that the patients with TES hypermethylation had a short overall survival (P < 0.05). This abnormality is also confirmed in glioblastoma cell lines (U87 and U251). Treating these cells with 5-aza-dC released TES protein expression resulted in significant inhibition of cell growth (P = 0.013).</p><p><b>CONCLUSIONS</b>Hypermethylation of TES gene promoter highly correlated with worse outcome in pGBM patients. TES might represent a valuable prognostic marker for glioblastoma.</p>
